Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 27, 2025
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal …
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
GlobeNewswire
·
March 27, 2025
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and …
AEON Biopharma Announces CEO Transition
GlobeNewswire
·
March 27, 2025
– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, …
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
GlobeNewswire
·
March 27, 2025
Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in …
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
·
March 27, 2025
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, …
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 27, 2025
MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial …
Better Choice Company Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
Fourth Quarter 2024 Revenue Growth of 26% Year-Over-Year to $7.2 million Fourth Quarter 2024 Loss per Share Improves 97% Year-Over-Year to $(0.50) Fourth Quarter 2024 Adjusted EBITDA Loss Improves 80% to $(0.7) million Year-Over-Year1 Full Year 2024 Loss …
Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders’ Meeting
GlobeNewswire
·
March 27, 2025
Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext …
Galapagos publiceert 2024 jaarverslag en kondigt jaarlijkse Gewone Algemene Vergadering aan
GlobeNewswire
·
March 27, 2025
Mechelen, België; 27 maart 2025, 21:01 CET; gereglementeerde informatie - Galapagos NV (Euronext …
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
GlobeNewswire
·
March 27, 2025
BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small molecule kinase inhibitor therapeutics to treat pulmonary arterial hypertension (“ …
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration
GlobeNewswire
·
March 27, 2025
U.S. IND Represents Regulatory Clearance For BEAM-302 Spanning Six Countries and Second Open IND for a Beam In Vivo Base Editing Program in the U.S. CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology …
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
GlobeNewswire
·
March 27, 2025
Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025 Company expects to complete analysis of full data set from the Phase 2 study of SPR720 …
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 27, 2025
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
DocGenie rolls out proactive and comprehensive care plans for the Elderly delivered at home
EIN Presswire
·
March 27, 2025
Comprehensive understanding of the patient's history and life style and continuity of care through senior geriatrics specialists helps in high quality care. GURGAON, HARYANA, INDIA, March 27, 2025 /EINPresswire.com/ -- In today’s fast-paced world, …
Mitolyn Reviews (SHOCKING DISCOVERY): Can This Mitochondria Hack Really Boost Energy & Burn Fat Naturally?
GlobeNewswire
·
March 27, 2025
Vancouver, Washington, March 27, 2025 (GLOBE NEWSWIRE) -- mitolyn (8) For years, weight loss supplements have promised quick fixes and overnight transformations, but most fail to deliver sustainable results. The real issue? They ignore the body’s core …
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
GlobeNewswire
·
March 27, 2025
EXTON, PA, March 27, 2025 (GLOBE NEWSWIRE) -- In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA …
Esteve Química Wins 2025 CDMO Leadership Award Amid €100M U.S.-Focused Manufacturing Expansion
GlobeNewswire
·
March 27, 2025
BARCELONA, Spain and NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Esteve Química, the CDMO division of leading specialty pharmaceutical company ESTEVE, has been named the Champion of the 2025 CDMO Leadership Award in the Small Molecule API – Global …
Prime Biome Gummies (EXPOSED): What Real Users Just Revealed About Prime Biome’s Gut & Skin Reset Formula
GlobeNewswire
·
March 27, 2025
Vancouver, March 27, 2025 (GLOBE NEWSWIRE) -- Prime Biome At a time when nearly every health product claims to support digestion, reduce inflammation, or rewind the clock on aging, one name is rising through the noise: Prime Biome. Promoted as a next- …
Prime Biome Reviews (SHOCKING TRUTH): What 67,000 Buyers Just Revealed About Side Effects & Gut Health
GlobeNewswire
·
March 27, 2025
Norfolk, March 27, 2025 (GLOBE NEWSWIRE) -- Prime Biome The health and beauty industry is packed with trendy supplements, but very few come with real medical backing and a reputation for delivering long-term results. Prime Biome has taken center stage as …
AsedaSciences® and CellPort Software Announce Co-Marketing Agreement to Advance the Management of Cell-Based Assays
EIN Presswire
·
March 27, 2025
CellPort’s novel cell management software will be integrated into AsedaSciences’ 3RnD® platform, enhancing data traceability for cell-based New Approach Methods SCHINDELLEGI, SCHWYZ, SWITZERLAND, March 27, 2025 /EINPresswire.com/ -- AsedaSciences, a …